Pelthos Therapeutics Inc. (PTHS)
US — Healthcare Sector
Automate Your Wheel Strategy on PTHS
With Tiblio's Option Bot, you can configure your own wheel strategy including PTHS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTHS
- Rev/Share 0.0
- Book/Share -10.1391
- PB -2.7251
- Debt/Equity -0.3549
- CurrentRatio 0.1125
- ROIC 2.1333
- MktCap 17918083.0
- FreeCF/Share -3.0092
- PFCF -9.2963
- PE -1.9581
- Debt/Assets 2.8009
- DivYield 0
- ROE 2.4375
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PTHS | Oppenheimer | -- | Outperform | -- | $50 | Sept. 2, 2025 |
News
About Pelthos Therapeutics Inc. (PTHS)
- IPO Date 2025-07-02
- Website https://pelthos.com
- Industry Biotechnology
- CEO Francis Knuettel II
- Employees 4
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.